MLchartDataset catalogue

pan-KRAS inhibitor PF-07985045

Term · Oncology and biomedicine · MLC-T-ONC-015799

An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor PF-07985045 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Table 1. Record
IdentifierMLC-T-ONC-015799
FieldOncology and biomedicine
SynonymsKRAS inhibitor PF-07985045
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015799",
  "term": "pan-KRAS inhibitor PF-07985045",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor PF-07985045 targets, binds to and inhibits various forms of KRAS mutations, thereby inhibiting KRAS-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.",
  "synonyms": [
    "KRAS inhibitor PF-07985045"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pan-kras-inhibitor-pf-07985045/"
}

Record 12,592 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.